Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis

Hampel, Frank C.; Kittner, Barbara; Bavel, Julius H. van

doi:10.1016/s1081-1206(10)60385-7

Cited by 25 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First generation antihistamines are not recommended due to its sedative effect [2, 7, 8]. A second generation antihistamine, fexofenadine, had been tested to be safe in children 2 years old or older for management of AR [46] and from 6 months for chronic urticaria . Cetirizine and desloratidine have approval of use for AR in children as young as 6 months of age.…”

Section: Introductionmentioning

confidence: 99%

Rhinitis in children less than 6 years of age: current knowledge and challenges

Hardjojo

Bever

Lee

2011

Asia Pacific Allergy

View full text Add to dashboard Cite

Rhinitis is a disease of the upper airway characterized by runny and/or blocked nose and/or sneezing. Though not viewed as a life threatening condition, it is also recognized to impose significant burden to the quality of life of sufferers and their caretakers and imposes an economic cost to society. Through a PubMed online search of the literature from 2006 to September 2011, this paper aims to review the published literature on rhinitis in young children below the age of 6 years. It is apparent from epidemiology studies that rhinitis in this age group is a relatively common problem. The condition has a heterogenous etiology with classification into allergic and non-allergic rhinitis. Respiratory viral infections may play a role in the pathogenesis of long standing rhinitis, but definitive studies are still lacking. Treatment guidelines for management are lacking for this age group, and is a significant unmet need. Although the consensus is that co-morbidities including otitis media with effusion, adenoidal hypertrophy and asthma, are important considerations of management of these children. Pharmacotherapy is limited for young children especially for those below the age of 2 years. This review underscores the lack of understanding of rhinitis in early childhood and therefore the need for further research in this area.

show abstract

Section: Introductionmentioning

confidence: 99%

Rhinitis in children less than 6 years of age: current knowledge and challenges

Hardjojo

Bever

Lee

2011

Asia Pacific Allergy

View full text Add to dashboard Cite

show abstract

“…However, hospitalization is only indicated if either respiratory distress (wheezing or stridor) or other signs of anaphylaxis (hypotension, hypotonia, or gastrointestinal symptoms) are observed [38]. Studies [42][43][44][45][46] in young children of efficacy and safety of other secondgeneration antihistamines, mainly levocetirizine, followed. Despite first-generation antihistamines having a lower therapeutic window than secondgeneration drugs, they are still widely available and still preferred by many physicians in children as young as 2 years of age.…”

Section: Managementmentioning

confidence: 99%

Childhood urticaria

Marrouche

Grattan

2012

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Urticaria is a common disease that affects children and adults. However, paediatric urticaria has specific features and remains poorly understood. Acute spontaneous urticaria is the most common clinical presentation in childhood. It is caused by viral infection in most cases with an identifiable trigger. By contrast, chronic spontaneous urticaria in children may be autoimmune, but more studies are needed to understand the clinical significance of functional autoantibodies in this subgroup of patients. Investigations should always be guided by history. Treatment remains largely symptomatic. H1-antihistamines are the mainstay of therapy but are insufficient to control symptoms in all patients. There is an urgent need for more efficacious therapies.

show abstract

“…Also, Potter found none of these ADRs in a group of 150 older children (6–12 years of age) receiving levocetirizine followed up for 4 weeks 22. In two large trials in almost 400 children, aged 6–24 months, receiving 15 or 30 mg or placebo, no serious ADRs or changes on the electrocardiogram were established 23. Levocetirizine was compared with placebo in a group of 177 children with seasonal allergic rhinitis and the authors found no differences in ADRs between the groups 24.…”

Section: Discussionmentioning

confidence: 99%